Prevalence of treated patients with Alzheimer's disease: current trends and COVID-19 impact.
Humans
Male
Female
Alzheimer Disease
/ drug therapy
Donepezil
/ therapeutic use
Rivastigmine
/ therapeutic use
Memantine
/ therapeutic use
Cholinesterase Inhibitors
/ therapeutic use
Retrospective Studies
Pandemics
Prevalence
Piperidines
/ therapeutic use
Phenylcarbamates
/ therapeutic use
Indans
/ therapeutic use
COVID-19
/ epidemiology
Galantamine
/ therapeutic use
Alzheimer disease
Cholinesterase inhibitors
Incidence
Memantine
Prevalence
Spain
Treatment
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
03 08 2023
03 08 2023
Historique:
received:
13
11
2022
accepted:
11
07
2023
medline:
7
8
2023
pubmed:
4
8
2023
entrez:
3
8
2023
Statut:
epublish
Résumé
There are few updated studies on the prevalence and management of Alzheimer's disease (AD), which could be underdiagnosed or undertreated. The COVID-19 pandemic may have worsened the deficiencies in the diagnosis and treatment of these patients. Electronic medical records (EMR) offer an opportunity to assess the impact and management of medical processes and contingencies in the population. To estimate AD prevalence in Spain over a 6-year period, based on treated patients, according to usual clinical practice. Additionally, to describe the management of AD-treated patients and the evolution of that treatment during the 2020 COVID-19 pandemic. Retrospective study using the Spanish IQVIA EMR database. Patients treated with donepezil, galantamine, rivastigmine, and/or memantine were included in the study. Annual AD prevalence (2015-2020) was estimated and extrapolated to the national population level. Most frequent treatments and involved specialties were described. To assess the effect of COVID-19, the incidence of new AD cases in 2020 was calculated and compared with newly diagnosed cases in 2019. Crude AD prevalence (2015-2020) was estimated at 760.5 per 100,000 inhabitants, and age-standardized prevalence (2020) was 664.6 (male 595.7, female 711.0). Monotherapy was the most frequent way to treat AD (86.2%), in comparison with dual therapy (13.8%); rivastigmine was the most prescribed treatment (37.3%), followed by memantine (36.4%) and donepezil (33.0%). Rivastigmine was also the most utilized medication in newly treated patients (46.7%), followed by donepezil (29.8%), although donepezil persistence was longer (22.5 vs. 20.6 months). Overall, donepezil 10 mg, rivastigmine 9.5 mg, and memantine 20 mg were the most prescribed presentations. The incidence rate of AD decreased from 148.1/100,000 (95% confidence interval [CI] 147.0-149.2) in 2019 to 118.4/100,000 (95% CI 117.5-119.4) in 2020. The obtained prevalence of AD-treated patients was consistent with previous face-to-face studies. In contrast with previous studies, rivastigmine, rather than donepezil, was the most frequent treatment. A decrease in the incidence of AD-treated patients was observed during 2020 in comparison with 2019, presumably due to the significant impact of the COVID-19 pandemic on both diagnosis and treatment. EMR databases emerge as valuable tools to monitor in real time the incidence and management of medical conditions in the population, as well as to assess the health impact of global contingencies and interventions.
Sections du résumé
BACKGROUND
There are few updated studies on the prevalence and management of Alzheimer's disease (AD), which could be underdiagnosed or undertreated. The COVID-19 pandemic may have worsened the deficiencies in the diagnosis and treatment of these patients. Electronic medical records (EMR) offer an opportunity to assess the impact and management of medical processes and contingencies in the population.
OBJECTIVE
To estimate AD prevalence in Spain over a 6-year period, based on treated patients, according to usual clinical practice. Additionally, to describe the management of AD-treated patients and the evolution of that treatment during the 2020 COVID-19 pandemic.
METHODS
Retrospective study using the Spanish IQVIA EMR database. Patients treated with donepezil, galantamine, rivastigmine, and/or memantine were included in the study. Annual AD prevalence (2015-2020) was estimated and extrapolated to the national population level. Most frequent treatments and involved specialties were described. To assess the effect of COVID-19, the incidence of new AD cases in 2020 was calculated and compared with newly diagnosed cases in 2019.
RESULTS
Crude AD prevalence (2015-2020) was estimated at 760.5 per 100,000 inhabitants, and age-standardized prevalence (2020) was 664.6 (male 595.7, female 711.0). Monotherapy was the most frequent way to treat AD (86.2%), in comparison with dual therapy (13.8%); rivastigmine was the most prescribed treatment (37.3%), followed by memantine (36.4%) and donepezil (33.0%). Rivastigmine was also the most utilized medication in newly treated patients (46.7%), followed by donepezil (29.8%), although donepezil persistence was longer (22.5 vs. 20.6 months). Overall, donepezil 10 mg, rivastigmine 9.5 mg, and memantine 20 mg were the most prescribed presentations. The incidence rate of AD decreased from 148.1/100,000 (95% confidence interval [CI] 147.0-149.2) in 2019 to 118.4/100,000 (95% CI 117.5-119.4) in 2020.
CONCLUSIONS
The obtained prevalence of AD-treated patients was consistent with previous face-to-face studies. In contrast with previous studies, rivastigmine, rather than donepezil, was the most frequent treatment. A decrease in the incidence of AD-treated patients was observed during 2020 in comparison with 2019, presumably due to the significant impact of the COVID-19 pandemic on both diagnosis and treatment. EMR databases emerge as valuable tools to monitor in real time the incidence and management of medical conditions in the population, as well as to assess the health impact of global contingencies and interventions.
Identifiants
pubmed: 37537656
doi: 10.1186/s13195-023-01271-0
pii: 10.1186/s13195-023-01271-0
pmc: PMC10401753
doi:
Substances chimiques
Donepezil
8SSC91326P
Rivastigmine
PKI06M3IW0
Memantine
W8O17SJF3T
Cholinesterase Inhibitors
0
Piperidines
0
Phenylcarbamates
0
Indans
0
Galantamine
0D3Q044KCA
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
130Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413–46. https://doi.org/10.1016/S0140-6736(20)30367-6 .
doi: 10.1016/S0140-6736(20)30367-6
pubmed: 32738937
pmcid: 7392084
Soria Lopez JA, González HM, Léger GC. Alzheimer’s disease. Handb Clin Neurol. 2019;167:231–55. https://doi.org/10.1016/B978-0-12-804766-8.00013-3 .
doi: 10.1016/B978-0-12-804766-8.00013-3
pubmed: 31753135
Agüero-Torres H, von Strauss E, Viitanen M, Winblad B, Fratiglioni L. Institutionalization in the elderly: the role of chronic diseases and dementia. Cross-sectional and longitudinal data from a population-based study. J Clin Epidemiol. 2001;54(8):795–801. https://doi.org/10.1016/s0895-4356(00)00371-1 .
doi: 10.1016/s0895-4356(00)00371-1
pubmed: 11470388
Kurichi JE, Kwong PL, Xie D, Bogner HR. Predictive indices for functional improvement and deterioration, institutionalization, and death among elderly Medicare beneficiaries. PM R. 2017;9(11):1065–76. https://doi.org/10.1016/j.pmrj.2017.04.005 .
doi: 10.1016/j.pmrj.2017.04.005
pubmed: 28456694
pmcid: 5658275
Wittenberg R, Hu B, Jagger C, et al. Projections of care for older people with dementia in England: 2015 to 2040. Age Ageing. 2020;49(2):264–9. https://doi.org/10.1093/ageing/afz154 .
doi: 10.1093/ageing/afz154
pubmed: 31808792
Rountree SD, Chan W, Pavlik VN, Darby EJ, Siddiqui S, Doody RS. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res Ther. 2009;1(2):7. https://doi.org/10.1186/alzrt7 . Published 2009 Oct 21.
doi: 10.1186/alzrt7
pubmed: 19845950
pmcid: 2874259
Amjad H, Roth DL, Sheehan OC, Lyketsos CG, Wolff JL, Samus QM. Underdiagnosis of dementia: an observational study of patterns in diagnosis and awareness in US older adults. J Gen Intern Med. 2018;33(7):1131–8. https://doi.org/10.1007/s11606-018-4377-y .
doi: 10.1007/s11606-018-4377-y
pubmed: 29508259
pmcid: 6025653
Rodríguez-Gómez O, Rodrigo A, Iradier F, Santos-Santos MA, Hundemer H, Ciudin A, et al. The MOPEAD project: advancing patient engagement for the detection of “hidden” undiagnosed cases of Alzheimer’s disease in the community. Alzheimers Dement. 2019;15(6):828–39. https://doi.org/10.1016/j.jalz.2019.02.003 .
doi: 10.1016/j.jalz.2019.02.003
pubmed: 31076376
Atri A. The Alzheimer’s disease clinical spectrum: diagnosis and management. Med Clin North Am. 2019;103(2):263–93. https://doi.org/10.1016/j.mcna.2018.10.009 .
doi: 10.1016/j.mcna.2018.10.009
pubmed: 30704681
Heintz H, Monette P, Epstein-Lubow G, Smith L, Rowlett S, Forester BP. Emerging collaborative care models for dementia care in the primary care setting: a narrative review. Am J Geriatr Psychiatry. 2020;28(3):320–30. https://doi.org/10.1016/j.jagp.2019.07.015 .
doi: 10.1016/j.jagp.2019.07.015
pubmed: 31466897
National Institute for Health and Care Excellence. Guidelines. Dementia: assessment, management and support for people living with dementia and their carers; NICE. 2018. https://www.guidelines.co.uk/mental-health/nice-dementiaguideline/454244.article Accessed 31 May 2022
Truong C, Recto C, Lafont C, Canoui-Poitrine F, Belmin JB, Lafuente-Lafuente C. Effect of cholinesterase inhibitors on mortality in patients with dementia: a systematic review of randomized and nonrandomized trials [published online ahead of print, 2022 Sep 12]. Neurology. 2022. doi: https://doi.org/10.1212/WNL.0000000000201161
Bond J, Stave C, Sganga A, O’Connell B, Stanley RL. Inequalities in dementia care across Europe: key findings of the Facing Dementia Survey. Int J Clin Pract Suppl. 2005;146:8–14. https://doi.org/10.1111/j.1368-504x.2005.00480.x .
doi: 10.1111/j.1368-504x.2005.00480.x
Jones RW, Mackell J, Berthet K, Knox S. Assessing attitudes and behaviours surrounding Alzheimer’s disease in Europe: key findings of the Important Perspectives on Alzheimer’s Care and Treatment (IMPACT) survey. J Nutr Health Aging. 2010;14(7):525–30. https://doi.org/10.1007/s12603-010-0263-y .
doi: 10.1007/s12603-010-0263-y
pubmed: 20818466
Martínez-Lage P, Martín-Carrasco M, Arrieta E, Rodrigo J, Formiga F. Mapa de la enfermedad de Alzheimer y otras demencias en España. Proyecto MapEA [Map of Alzheimer’s disease and other dementias in Spain. MapEA Project]. Rev Esp Geriatr Gerontol. 2018;53(1):26–37. https://doi.org/10.1016/j.regg.2017.07.006 . Article in Spanish.
doi: 10.1016/j.regg.2017.07.006
pubmed: 29107401
Lleó A. [Alzheimer’s disease: an ignored condition]. Med Clin (Barc). 2018;150(11):432–3. https://doi.org/10.1016/j.medcli.2017.10.028 . Article in Spanish.
doi: 10.1016/j.medcli.2017.10.028
pubmed: 29196039
Ministerio de Sanidad, Consumo y Bienestar Social. Plan Integral de Alzheimer y Otras Demencias (2019–2023); Ministerio de Sanidad, Consumo y Bienestar Social 2019; https://www.sanidad.gob.es/profesionales/saludPublica/docs/Plan_Integral_Alhzeimer_Octubre_2019.pdf Accessed 31 May 2022
Mok VCT, Pendlebury S, Wong A, Alladi S, Au L, Bath PM, et al. Tackling challenges in care of Alzheimer’s disease and other dementias amid the COVID-19 pandemic, now and in the future. Alzheimers Dement. 2020;16(11):1571–81. https://doi.org/10.1002/alz.12143 .
doi: 10.1002/alz.12143
pubmed: 32789951
pmcid: 7436526
Benaque A, Gurruchaga MJ, Abdelnour C, Hernández I, Cañabate P, Alegret M, et al. Dementia care in times of COVID-19: experience at Fundació ACE in Barcelona. Spain J Alzheimers Dis. 2020;76(1):33–40. https://doi.org/10.3233/JAD-200547 .
doi: 10.3233/JAD-200547
pubmed: 32538856
Cuffaro L, Di Lorenzo F, Bonavita S, Tedeschi G, Leocani L, Lavorgna L. Dementia care and COVID-19 pandemic: a necessary digital revolution. Neurol Sci. 2020;41(8):1977–9. https://doi.org/10.1007/s10072-020-04512-4 .
doi: 10.1007/s10072-020-04512-4
pubmed: 32556746
pmcid: 7298162
Numbers K, Brodaty H. The effects of the COVID-19 pandemic on people with dementia. Nat Rev Neurol. 2021;17(2):69–70. https://doi.org/10.1038/s41582-020-00450-z .
doi: 10.1038/s41582-020-00450-z
pubmed: 33408384
pmcid: 7786184
Donaldson LJ, Rutter PR. Donaldsons’ essential public health. 4th ed. Boca Raton: CRC Press; 2017.
GBD 2016 Dementia Collaborators. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(1):88–106. https://doi.org/10.1016/S1474-4422(18)30403-4 .
doi: 10.1016/S1474-4422(18)30403-4
Ponjoan A, Garre-Olmo J, Blanch J, Fages E, Alves-Cabratosa L, Martí-Lluch R, et al. Is it time to use real-world data from primary care in Alzheimer’s disease? Alzheimers Res Ther. 2020;12(1):60. https://doi.org/10.1186/s13195-020-00625-2 .
doi: 10.1186/s13195-020-00625-2
pubmed: 32423489
pmcid: 7236302
de Pedro-Cuesta J, Virués-Ortega J, Vega S, et al. Prevalence of dementia and major dementia subtypes in Spanish populations: a reanalysis of dementia prevalence surveys, 1990–2008. BMC Neurol. 2009;9:55. https://doi.org/10.1186/1471-2377-9-55 .
doi: 10.1186/1471-2377-9-55
pubmed: 19840375
pmcid: 2770986
Maciejewska K, Czarnecka K, Szymański P. A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease. Pharmacol Rep. 2021;73(6):1565–81. https://doi.org/10.1007/s43440-021-00293-5 .
doi: 10.1007/s43440-021-00293-5
pubmed: 34121170
pmcid: 8599320
Donegan K, Fox N, Black N, Livingston G, Banerjee S, Burns A. Trends in diagnosis and treatment for people with dementia in the UK from 2005 to 2015: a longitudinal retrospective cohort study. Lancet Public Health. 2017;2(3):e149–56. https://doi.org/10.1016/S2468-2667(17)30031-2 .
doi: 10.1016/S2468-2667(17)30031-2
pubmed: 29253388
Podhorna J, Winter N, Zoebelein H, Perkins T. Alzheimer’s treatment: real-world physician behavior across countries. Adv Ther. 2020;37(2):894–905. https://doi.org/10.1007/s12325-019-01213-z .
doi: 10.1007/s12325-019-01213-z
pubmed: 31933052
pmcid: 7004436
Cummings J, Emre M, Aarsland D, Tekin S, Dronamraju N, Lane R. Effects of rivastigmine in Alzheimer’s disease patients with and without hallucinations. J Alzheimers Dis. 2010;20(1):301–11. https://doi.org/10.3233/JAD-2010-1362 .
doi: 10.3233/JAD-2010-1362
pubmed: 20164585
Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, et al. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med. 2012;366(10):893–903. https://doi.org/10.1056/NEJMoa1106668 .
doi: 10.1056/NEJMoa1106668
pubmed: 22397651
Gauthier S, Molinuevo JL. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer’s disease. Alzheimers Dement. 2013;9(3):326–31. https://doi.org/10.1016/j.jalz.2011.11.005 .
doi: 10.1016/j.jalz.2011.11.005
pubmed: 23110864
McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond L, et al. Memantine for dementia. Cochrane Database Syst Rev. 2019;3(3):CD003154. https://doi.org/10.1002/14651858.CD003154.pub6 . Published 2019 Mar 20.
doi: 10.1002/14651858.CD003154.pub6
pubmed: 30891742
Mucha L, Shaohung S, Cuffel B, McRae T, Mark TL, Del Valle M. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer’s disease. J Manag Care Pharm. 2008;14(5):451–61. https://doi.org/10.18553/jmcp.2008.14.5.451 .
doi: 10.18553/jmcp.2008.14.5.451
pubmed: 18597574
Fisher A, Carney G, Bassett K, Dormuth CR. Tolerability of cholinesterase inhibitors: a population-based study of persistence, adherence, and switching. Drugs Aging. 2017;34(3):221–31. https://doi.org/10.1007/s40266-017-0438-x .
doi: 10.1007/s40266-017-0438-x
pubmed: 28138912
Byun J, Lee DY, Jeong CW, Kim Y, Rhee HY, Moon KW, et al. Analysis of treatment pattern of anti-dementia medications in newly diagnosed Alzheimer’s dementia using OMOP CDM. Sci Rep. 2022;12(1):4451. https://doi.org/10.1038/s41598-022-08595-1 . Published 2022 Mar 15.
doi: 10.1038/s41598-022-08595-1
pubmed: 35292697
pmcid: 8924152
Kandiah N, Pai MC, Senanarong V, Looi I, Ampil E, Park KW, et al. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia. Clin Interv Aging. 2017;12:697–707. https://doi.org/10.2147/CIA.S129145 .
doi: 10.2147/CIA.S129145
pubmed: 28458525
pmcid: 5402908
Sicras-Mainar A, Vergara J, Leon-Colombo T, Febrer L, Rejas-Gutierrez J. Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer’s disease patients treated with donepezil, rivastigmine, galantamine and memantine. Rev Neurol. 2006;43(8):449–53. Article in Spanish.
pubmed: 17033976
Matsuzono K, Sato K, Kono S, Hishikawa N, Ohta Y, Yamashita T, et al. Clinical benefits of rivastigmine in the real world dementia clinics of the Okayama Rivastigmine Study (ORS). J Alzheimers Dis. 2015;48(3):757–63. https://doi.org/10.3233/JAD-150518 .
doi: 10.3233/JAD-150518
pubmed: 26402119
Gil P, Ayuso JL, Marey JM, Antón M, Quilo CG. Variability in the diagnosis and management of patients with Alzheimer’s disease and cerebrovascular disease: results from the GALATEA multicentre, observational study. Clin Drug Investig. 2008;28(7):429–37. https://doi.org/10.2165/00044011-200828070-00004 .
doi: 10.2165/00044011-200828070-00004
pubmed: 18544003
Koller D, Hua T, Bynum JP. Treatment patterns with antidementia drugs in the United States: Medicare cohort study. J Am Geriatr Soc. 2016;64(8):1540–8. https://doi.org/10.1111/jgs.14226 .
doi: 10.1111/jgs.14226
pubmed: 27341454
pmcid: 5045869
National Alzheimer’s Project Act. USA: 2011. Public Law 111 -375-Jan 4 2011
Tsapanou A, Papatriantafyllou JD, Yiannopoulou K, Sali D, Kalligerou F, Ntanasi E, et al. The impact of COVID-19 pandemic on people with mild cognitive impairment/dementia and on their caregivers. Int J Geriatr Psychiatry. 2021;36(4):583–7. https://doi.org/10.1002/gps.5457 .
doi: 10.1002/gps.5457
pubmed: 33166418
Xia X, Wang Y, Zheng J. COVID-19 and Alzheimer’s disease: how one crisis worsens the other. Transl Neurodegener. 2021;10(1):15. https://doi.org/10.1186/s40035-021-00237-2 . Published 2021 Apr 30.
doi: 10.1186/s40035-021-00237-2
pubmed: 33941272
pmcid: 8090526
Axenhus M, Schedin-Weiss S, Tjernberg L, Wimo A, Eriksdotter M, Bucht G, Winblad B. Changes in dementia diagnoses in Sweden during the COVID-19 pandemic. BMC Geriatr. 2022;22(1):365. https://doi.org/10.1186/s12877-022-03070-y .
doi: 10.1186/s12877-022-03070-y
pubmed: 35473668
pmcid: 9039601
Schliep KC, Ju S, Foster NL, Smith KR, Varner MW, Østbye T, Tschanz JT. How good are medical and death records for identifying dementia? Alzheimers Dement. 2022;18(10):1812–23. https://doi.org/10.1002/alz.12526 .
doi: 10.1002/alz.12526
pubmed: 34873816
Jones A, Bronskill SE, Maclagan LC, Jaakkimainen L, Kirkwood D, Mayhew A, Costa AP, Griffith LE. Examining the immediate and ongoing impact of the COVID-19 pandemic on population-based estimates of dementia: a population-based time series analysis in Ontario, Canada. BMJ Open. 2023;13(1):e067689. https://doi.org/10.1136/bmjopen-2022-067689 .
doi: 10.1136/bmjopen-2022-067689
pubmed: 36639204